<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>postoperative radiotherapy &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/postoperative-radiotherapy/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Fri, 09 Oct 2026 23:15:51 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.3</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>postoperative radiotherapy &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Chemoimmunotherapy Before Surgery Lets Some Head and Neck Cancer Patients Skip High-Dose Radiation</title>
		<link>https://bioengineer.org/chemoimmunotherapy-before-surgery-lets-some-head-and-neck-cancer-patients-skip-high-dose-radiation/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Fri, 09 Oct 2026 23:15:51 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[disease-free survival]]></category>
		<category><![CDATA[Head and neck cancer]]></category>
		<category><![CDATA[immunotherapy]]></category>
		<category><![CDATA[Major pathological response]]></category>
		<category><![CDATA[neoadjuvant chemo-immunotherapy]]></category>
		<category><![CDATA[PD-1 inhibitor]]></category>
		<category><![CDATA[phase II trial]]></category>
		<category><![CDATA[postoperative radiotherapy]]></category>
		<category><![CDATA[radiation de-escalation]]></category>
		<category><![CDATA[sintilimab]]></category>
		<category><![CDATA[squamous cell carcinoma]]></category>
		<category><![CDATA[treatment toxicity]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=411578</guid>

					<description><![CDATA[A phase II trial found that preoperative chemo-immunotherapy with sintilimab achieved major pathological responses in 59.1 percent of locally advanced head and neck cancer patients, allowing responders to receive reduced-dose postoperative radiation with 100 percent two-year survival and fewer side effects.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">411578</post-id>	</item>
	</channel>
</rss>
